Selling pressure pushes AstraZeneca stock lower in today's trading

Traders Union
All News
Financial News
Astrazeneca slides 2.15% today

Highlights

AstraZeneca's experimental obesity pill achieved 10.5% average weight loss over 26 weeks in a mid-stage trial.
Ultomiris delivered a 46.6% reduction in proteinuria in IgA nephropathy, bolstering regulatory submissions and pipeline momentum.
Shares are pressured, trading below key averages, with indicators split and price expected to consolidate between GBX 13,452.00 and GBX 13,727.00.

Mixed drug trial results and investments fail to offset bearish pressure

AstraZeneca reported that its experimental obesity pill resulted in a 10.5% average weight loss for patients over 26 weeks in a mid-stage clinical trial. The company also announced its drug Ultomiris achieved a 46.6% reduction in proteinuria in adults with immunoglobulin A nephropathy in an interim Phase 3 analysis, supporting regulatory submissions. AstraZeneca additionally committed $50 billion to expand research, manufacturing, and patient access in the United States, while integrating AI into its drug development process, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes sustained selling pressure in AstraZeneca as the stock trades below short- and medium-term averages. He remains wary despite recent announcements on drug pipeline progress and US investment, as persistent bearish momentum through MACD and ADX outweighs news-driven optimism. Kharitonov points to the risk of further downside if long-term support at the 200-day average fails. In his view, investor confidence seems fragile, with technical exhaustion possible after the latest gap down. "Traders should stay cautious here — the current setup favors defense over aggressive bullish bets until clear reversal signals emerge."

Viktoras Karapetjanc, expert at Traders Union, sees continued fundamental strength in AstraZeneca’s story. He highlights the company’s solid drug pipeline progress and decisive $50 billion US expansion, which reinforce its long-term growth profile. Karapetjanc believes the presence above the 200-day average signals that the bullish structure remains intact, despite short-term pressure. He expects further opportunities for growth as new treatments approach approval and research investments ramp up. "I see strong setups evolving, and further upside is likely as the market starts pricing in AstraZeneca's innovation and scale."

Jainam Mehta, market strategist, takes a balanced view with focus on key technical thresholds ahead of major catalysts. He emphasizes the importance of the GBX 13,547.89 level as long-term support and notes mixed signals between momentum and oscillator readings. Mehta sees tactical possibilities for both breakout and breakdown trades within the outlined volatility band. "A contrarian approach may pay off if price action overreacts, but discipline is essential with risk positioned around GBX 13,452.00 support."

Bearish momentum intensifies amid diverging technical indicators

AstraZeneca is trading below its 20-day and 50-day simple moving averages (GBX 13,720.40 and GBX 14,136.84), indicating short- and medium-term pressure from sellers, yet it remains slightly above the 200-day moving average at GBX 13,547.89, which acts as long-term dynamic support. The Ichimoku Kijun level at GBX 12,676.00 serves as the next lower support, with the 50-day moving average forming a key resistance overhead. Momentum readings are mixed: the MACD gives a strong sell signal, and the Average Directional Index (ADX) confirms a pronounced bearish trend. The Relative Strength Index (RSI) is neutral at mid-50s but is echoed by an overbought Stochastic RSI, suggesting potential short-term exhaustion. Bull/Bear Power (BBP) shows buyers still dominate with a high positive value, though the indicator is also overbought. The daily move shows the stock down GBX 298, or 2.15%, after a downside opening gap of about GBX 268. Intraday, the price is trading in the upper part of its daily range with volatility at 0.82%. There is pressure after the open, and momentum signals diverge, with persistent buyer dominance clashing against bearish MACD and strong ADX readings.

Earlier, analysts noted that AstraZeneca’s technical resilience and expanding product pipeline positioned the stock for a potential bullish breakout, despite mixed momentum signals. The current environment reinforces this outlook with strong long-term support remaining in place, but traders should watch for a decisive move above the 50-day moving average or a breach below the 200-day as potential catalysts for a shift in the prevailing trend.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.